Noetik Secures $40 Million in Series A Funding to Revolutionize Cancer Therapeutics
Noetik, a pioneering AI-native biotechnology firm dedicated to advancing precision cancer therapies, has successfully closed a substantial $40 million Series A financing round. This oversubscribed round was spearheaded by Polaris Partners, with Amy Schulman, Managing Partner, joining Noetik’s board of directors. The funding also saw participation from notable new investors including Khosla Ventures, Wittington Ventures,…